MARKET

QNCX

QNCX

Quince
NASDAQ
3.560
-0.100
-2.73%
After Hours: 3.570 +0.01 +0.28% 18:01 12/26 EST
OPEN
3.660
PREV CLOSE
3.660
HIGH
3.682
LOW
3.340
VOLUME
388.25K
TURNOVER
--
52 WEEK HIGH
4.550
52 WEEK LOW
0.7203
MARKET CAP
198.23M
P/E (TTM)
-2.9190
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at QNCX last week (1215-1219)?
Weekly Report · 6d ago
Quince Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/15 19:38
D. Boral Capital Maintains Buy on Quince Therapeutics, Raises Price Target to $5
Benzinga · 12/15 19:28
Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital
TipRanks · 12/15 14:26
Quince Therapeutics announces last visit from last patient in NEAT trial
TipRanks · 12/15 13:10
Quince Therapeutics Says Last Patient Completed Last Visit In Pivotal Phase 3 NEAT Clinical Trial Of eDSP, In Patients With Ataxia-Telangiectasia; Expects To Report Topline Results From In Q1 2026
Benzinga · 12/15 13:07
Quince Therapeutics Completes Phase 3 NEAT Trial for Ataxia-Telangiectasia Drug
Reuters · 12/15 13:01
QUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026
Reuters · 12/15 13:00
More
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

Webull offers Quince Therapeutics Inc stock information, including NASDAQ: QNCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QNCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QNCX stock methods without spending real money on the virtual paper trading platform.